Ovid Therapeutics Inc. (OVID), Wednesday announced an agreement with with Immedica Pharma AB to sell future royalties related to sales of ganaxolone outside of China for $7 million in cash.
Additionally, Immedica would acquire or license the global ganaxolone intellectual property portfolio from Ovid, and amend the license to include additional indications.
Ovid stated that the capital infusion would support the company's ongoing operations. Meanwhile, the deal would strengthen Immedica's focus on ganaxolone, an adjunctive treatment for epileptic seizures associated with CDKL5 deficiency disorder.
In the pre-market hours, OVID is trading at $0.32, up 7.39 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.